



Board of Directors

Executive Committee

Kathryn G. Schubert, MPP
President and CEO
Society for Women's Health Research

Shontelle Dodson, PharmD
Board Chair
Senior Vice President, Health Systems
Astellas Pharma Inc.

Gretta Stone
Board Secretary-Treasurer
Director
Reservoir Communications Group

Roberta L. Gartside, MD
Immediate Past Board Chair
New Image Plastic Surgery Associates

Dawn Halkuff, MBA
Chief Commercial Officer
TherapeuticsMD

Jenelle S. Krishnamoorthy, PhD
Associate Vice President, Global Policy
Merck & Co. Inc.

—

Anne B. Cropp, PharmD
Chief Scientific Officer
Early Access Care LLC

Nieca Goldberg, MD
Medical Director
Joan H. Tisch Center for Women's
Health, NYU Langone Health

Linda G. Griffith, PhD
Professor of Biological Engineering
Massachusetts Institute of Technology

David C. Page, MD
Director, Whitehead Institute
Massachusetts Institute of Technology

Alan T. Wright, MD
Chief Medical Officer
Roche Diagnostics Corporation

Michael Ybarra, MD
Vice President,
Medical Affairs and Strategic Alliances
PhRMA

—

Florence Haseltine, PhD
Founding Honorary Board Director
Executive Director of Health Research,
University of Texas at Arlington

February 18, 2021

President Joe Biden
1600 Pennsylvania Ave., NW
Washington, D.C., 20500

Dear President Biden,

The Society for Women's Health Research (SWHR) thanks you for your recent appointment of Dr. Janet Woodcock as Acting Commissioner of the U.S. Food and Drug Administration (FDA).

Founded in 1990, SWHR is dedicated to promoting research on biological sex differences in disease and improving women's health through science, policy, and education. SWHR championed the framework for the scientific discipline of sex-based biology, which encourages the inclusion of female subjects in clinical trials and analyzes the differences between women and men in relation to disease.

Given the pressing national need to focus on improving diversity and inclusion in clinical trials research, as well as improving health care quality and access for all women, we are pleased to have Dr. Woodcock at the helm of the FDA. Over her three decades of leadership and field experience, Dr. Woodcock has raised the standard of excellence in drug safety and patient care. She has played a lead role in improving the drug review process by making it more open and transparent, while also creating unprecedented opportunities for patient participation and improving drug safety management both within and outside of the FDA.

In 2018 we recognized Dr. Woodcock's commitment and integrity throughout her career as a true health and public service visionary. SWHR believes that Dr. Woodcock's background, experience, and leadership are essential to the FDA during this crucial time in our nation's history.

Sincerely,

Kathryn G. Schubert, MPP
President and Chief Executive Officer
Society for Women's Health Research